Who
Andrea S. James
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Insight Molecular Diagnostics.
In numbers
- Trades disclosed
- 20
- Buys
- 3
- Sells
- 0
- Bought
- $346K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Jun 2024
- Last trade
- 26 Mar 2026
- Last filed
- 30 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —28,302 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $46K11,298 at $4.11 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —28,302 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —28,302 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —28,302 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $46K11,298 at $4.11 | filing |
| 31 Oct 2025filed 13 Nov 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 31 Oct 2025filed 13 Nov 2025 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 31 Oct 2025filed 13 Nov 2025 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $73K12,175 at $6.01 | filing |
| 31 Oct 2025filed 4 Nov 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 31 Oct 2025filed 4 Nov 2025 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 28 Sep 2025filed 30 Sep 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —235,000 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —113,207 at $0.00 | filing |
| 7 Feb 2025filed 11 Feb 2025 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Bought | $200K97,561 at $2.05 | filing |
| 5 Dec 2024filed 9 Dec 2024 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Bought | $46K20,000 at $2.29 | filing |
| 11 Oct 2024filed 15 Oct 2024 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 11 Oct 2024filed 15 Oct 2024 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Oct 2024filed 4 Oct 2024 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Bought | $100K33,670 at $2.97 | filing |
| 20 Jun 2024filed 24 Jun 2024 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyIMDX · tickerreport.com · 14 Oct 2026Reviewing Aktis Oncology (NASDAQ:AKTS) and Oncocyte (NASDAQ:IMDX)IMDX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Andrea S. James; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.